The medical artificial intelligence (AI) corporation VUNO announced on the 13th that its consolidated sales in the second quarter of this year increased by 45% compared to the same period last year, reaching 9.3 billion won, while its operating loss decreased by 95% to 170 million won.
Sales have increased for 10 consecutive quarters, marking the highest performance on a quarterly basis. The operating loss has also improved significantly, bringing the company closer to achieving its goal of turning a profit on a quarterly basis. VUNO noted that this is a result of efforts to enhance expense efficiency and improve profitability.
VUNO's flagship AI, "VUNOmed DeepCass," has driven sales. This is an AI software medical device that monitors the "24-hour risk of cardiac arrest" in general ward patients, contributing to patient safety. It entered the non-reimbursable market in 2022, becoming the first domestic medical AI to do so. Now, in its fourth year of introduction into the medical field, it is used in about 50,000 beds nationwide, and approximately 65,000 beds if including demonstrations.
Kim Jun-hong, chief financial officer (CFO) of VUNO, said, "DeepCass sales are steadily trending upward and stabilizing," adding, "We will do our best to achieve quarterly breakeven by the end of the year."